Royalty Pharma/$RPRX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Royalty Pharma
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
- Ticker
- $RPRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 100
- Headquarters
- New York, United States
- Website
- www.royaltypharma.com
Royalty Pharma Metrics
BasicAdvanced
$30B
35.68
$1.86
0.43
$0.93
1.41%
Price and volume
Market cap
$30B
Beta
0.43
52-week high
$67.71
52-week low
$36.03
Average daily volume
3M
Dividend rate
$0.93
Financial strength
Current ratio
2.797
Quick ratio
2.786
Long term debt to equity
0.877
Total debt to equity
0.916
Dividend payout ratio (TTM)
49.10%
Interest coverage (TTM)
4.30%
Profitability
EBITDA (TTM)
1,571.074
Gross margin (TTM)
95.82%
Net profit margin (TTM)
32.02%
Operating margin (TTM)
61.76%
Revenue per employee (TTM)
$25,360,000
Management effectiveness
Return on assets (TTM)
5.09%
Return on equity (TTM)
13.97%
Valuation
Price to earnings (TTM)
35.681
Price to revenue (TTM)
11.424
Price to book
4.34
Price to tangible book (TTM)
5.02
Price to free cash flow (TTM)
50.177
Free cash flow yield (TTM)
1.99%
Free cash flow per share (TTM)
1.326
Dividend yield (TTM)
1.39%
Forward dividend yield
1.41%
Growth
Revenue change (TTM)
10.01%
Earnings per share change (TTM)
-19.98%
3-year revenue growth (CAGR)
2.41%
3-year earnings per share growth (CAGR)
48.12%
3-year dividend per share growth (CAGR)
5.27%
What the Analysts think about Royalty Pharma
Analyst ratings (Buy, Hold, Sell) for Royalty Pharma stock.
Analyst projections of the future price of Royalty Pharma stock.
Bulls say / Bears say
Second-quarter royalty receipts rose 14% to $768 million, led by Tremfya, Voranigo, Imdelltra and Evrysdi. Royalty Pharma raised its 2026 receipts outlook for a second time, signalling stronger momentum in the existing portfolio. (Royalty Pharma)
The development-stage pipeline has grown to 19 potential therapies, with recent approvals and regulatory progress across several royalty-backed drugs. Successful launches and trial outcomes could add new royalty streams beyond the current portfolio. (Royalty Pharma)
The business generated $728 million of operating cash in the second quarter, double the year-earlier amount, while adjusted EBITDA rose 16%. That cash generation supports further royalty investment and shareholder returns. (Royalty Pharma)
Some established royalties are shrinking: Promacta receipts fell 75% and Imbruvica fell 16% year on year in the second quarter. US biosimilar competition for Tysabri is another expected headwind. (Royalty Pharma, The Motley Fool)
Royalty Pharma has material exposure to Vertex: it accounted for 30% of the current portion of financial royalty assets at the end of June. The cystic fibrosis franchise also generated $194 million of second-quarter receipts, unchanged from a year earlier, so weakness in this major exposure could weigh on growth. (SEC, Royalty Pharma)
The company had $9.2 billion of debt against $812 million of cash at the end of June and expects to pay $350–360 million in interest during 2026. These fixed financing costs could reduce flexibility if royalty receipts weaken. (Royalty Pharma)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2026.
Royalty Pharma Financial Performance
Revenues and expenses
Royalty Pharma Earnings Performance
Company profitability
Upcoming events
Royalty Pharma News
AllArticlesVideos
Funds containing Royalty Pharma
AllUSDEURGBP
Fund name | Fund size | $RPRX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 1.90% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 1.90% |
iShares MSCI World Health Care Sector Advanced€CBUF | $683M | 0.52% |
iShares MSCI World Health Care Sector Advanced£WHCA | $362M | 0.52% |
SPDR MSCI World Health Care$WHEA | $708M | 0.30% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.